Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368872 · ClinicalTrials.gov registry record · NA
Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly
A NA study of Sarcopenia, sponsored by Astavita.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT03368872: Completed NA study of Sarcopenia, sponsored by Astavita.
NCT03368872 is a NA study of Sarcopenia that has completed, run by Astavita. The registered enrollment target is 41 participants, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03368872, a NA study of Sarcopenia, has completed, sponsored by Astavita.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial and skeletal muscle function in elderly subjects with evidence of mitochondrial dysfunction/sarcopenia.
Primary Outcome
Skeletal muscle strength and performance will be evaluated by changes from baseline in muscle work rate calculated from the results of the leg muscle fatigue protocol testing: Baseline-Day 30-Day 120.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Exercise training
- OTHER Astaxanthin formulation
Study Locations (2)
Washington
- Fred Hutchinson Cancer Research Center Prevention Center - Seattle
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT03368872 record still lists
NCT03368872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Sarcopenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03368872 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03368872 about?
NCT03368872 is a clinical study titled "Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly". The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial and skeletal muscle function in elderly subjects with evidence of mitoch...
What is the current status of trial NCT03368872?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2015-10. Estimated completion is 2016-08.
What conditions does trial NCT03368872 study?
This clinical trial studies the following conditions: Sarcopenia.
What interventions are being tested in trial NCT03368872?
The interventions under investigation include: Placebo (OTHER), Exercise training (OTHER), Astaxanthin formulation (OTHER).
Who is sponsoring clinical trial NCT03368872?
This trial is sponsored by Astavita, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03368872 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03368872's enrollment target sits among peer trials
41 26th of 41 higher than 16 of 41 other Sarcopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Spinal Motoneuronal Activation in Older Adults
RECRUITING · NA
-
Strength Training and Resveratrol
RECRUITING · NA
-
Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment
RECRUITING · NA
-
Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
RECRUITING · NA
-
C-Protein in Fatigue and Aging
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia